Approved for One Thing, Used for Another: The Regulatory Gap at the Heart of Trazodone Prescribing
Trazodone carries a single FDA-approved indication for major depressive disorder, yet the majority of prescriptions written in the United States today are for insomnia, anxiety, and other conditions that fall entirely outside that label. Understanding how this regulatory and clinical divergence occurred—and what it means for patients and providers—requires a closer look at drug approval economics, evolving evidence, and the practical realities of psychiatric prescribing.